WXXWY News and Press, Wuxi Biologics Cayman Inc ADR From 07/15/22

Pfizer ( NYSE: PFE ) backed Chinese cancer drugmaker CStone Pharmaceuticals ( OTCPK:CSPHF ) is exploring strategic options, including a sale of the company, Bloomberg News reported citing people with knowledge of the matter. WuXi Healthcare Ventures, a unit of...

WuXi Vaccines said it received a GMP (Good Manufacturing Practice) certificate from Ireland Health Products Regulatory Authority for its QC potency lab in Dundalk, Ireland. WuXi Vaccines, which is a joint venture between WuXi Biologics ( OTCPK:WXXWY ) and Shanghai Hil...

Contract manufacturing organization WuXi XDC, a joint venture between WuXi Biologics ( OTCPK:WXXWY ) and WuXi STA, is collaborating with South Korean antibody-drug conjugates (ADC) maker AbTis. Under the agreement, AbTis will use WuXi XDC's integrated services fo...

WuXi Biologics ( OTCPK:WXXWY ) ( OTCPK:WXIBF ) gained nearly 12% on Tuesday after Reuters reported that the Wuxi, China-based life sciences company is one step closer to getting off the U.S. Commerce Department's "Unverified List." According to a department official, C...

WuXi Biologics Launches First Commercial Drug Product Facility for Pre-Filled Syringes PR Newswire WuXi Biologics offers global partners high-efficiency and high-quality manufacturing services for clinical trial and commercial supply by increasing pre-filled syringes (...

We had previously owned WuXi Biologic shares but sold it in the second quarter of 2019. We bought back WXIBF stock after a sharp price correction in the first quarter of 2021. The rapid development of several antibody drugs for COVID-19 gave a further, unexpected boost to WuXi...

Harding Loevner has been investing globally in high-quality, growing businesses based on disciplined industry research since 1989. Stock markets fell in the quarter, as the world watched in horror Russia’s invasion of Ukraine. China-based WuXi Biologics illustrates the perf...

Vir Biotechnology (NASDAQ:VIR) announced on Friday that its Chinese partner WuXi Biologics (OTCPK:WXXWY) (OTCPK:WXIBF) ended its partnership for development and manufacturing for several of company’s antibody drugs including the COVID-19 antibody therapy sotrovimab. Per the terms of th...

Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. Baron New Asia Fund (the “Fund”) declined 15.24% (Institutional Shares) during the first quarter of 2022. ...

China’s leading biotechnology and other health care companies have continued to grow revenues rapidly over the past two years and are expected to see strong growth in the years to come. Recently, concerns over domestic regulation, increased domestic competition, US Food and Dru...